FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.744,65 -1.245,43 (-2,08%)
Eterna Therapeutics Inc. (ERNA)
Dopo ore:
| Chiusura precedente | 1,7300 |
| Aperto | 1,7300 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 1,7300 - 1,8900 |
| Intervallo di 52 settimane | 0,8400 - 3,4500 |
| Volume | |
| Media Volume | 8.374 |
| Capitalizzazione | 9,684M |
| Beta (5 anni mensile) | 8,16 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,0800 |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireEterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel engineered iPS cell line to be evaluated by Lineage for potential development of cell transplant therapies for central nervous system diseases under collaboration initiated in early 2023 Lineage to make milestone payments to Eterna in connection with Eterna’s successful development and delivery to Lineage of certain materials CAMBRIDGE, Mass.,
GlobeNewswireEterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
Dorothy Clarke Dorothy Clarke CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Dorothy Clarke to its Board of Directors. “We are delighted to welcome Dorothy to our Board,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. “Dor
- GlobeNewswire
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction t
